文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

分次间膀胱与膀胱三角移位和形变对放疗暴露及后续急性泌尿生殖毒性的影响:一项3期随机试验中磁共振引导前列腺立体定向体部放疗患者的析因分析

Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-10-21

该析因分析纳入3期单中心随机试验MRI组77例接受磁共振引导前列腺立体定向体部放疗(40 Gy/5次)的患者,比较模拟MRI与5次治疗前机载MRI上膀胱和膀胱三角的轮廓差异及剂量参数。膀胱平均治疗体积较模拟体积小约30%,膀胱三角体积变化小但分次间移位和形变明显,中位Dice相似系数膀胱0.79、膀胱三角仅0.33;所选膀胱和膀胱三角剂量参数与≥2级泌尿生殖毒性无统计学显著关联。

要点

  • 膀胱平均治疗体积较模拟体积小约30%,膀胱三角体积与总膀胱体积正相关但保持相对一致。
  • 膀胱中位Dice相似系数0.79,膀胱三角仅0.33,提示膀胱三角分次间移位和形变明显。
  • 所选膀胱和膀胱三角剂量参数与≥2级泌尿生殖毒性无统计学显著关联。

核心结论

  • 膀胱三角体积变化小但分次间移位和形变明显,导致前列腺立体定向体部放疗中膀胱三角接受高剂量的相对体积在各分次间差异较大,可能影响泌尿生殖毒性且可能无法由放疗计划剂量学预测。

研究设计与样本

  • 3期单中心随机试验MRI组的析因分析,纳入77例接受磁共振引导前列腺立体定向体部放疗(40 Gy/5次)的患者。
  • 在0.35T模拟MRI和5次治疗前机载MRI上勾画膀胱和膀胱三角结构,计算Dice相似系数及模拟与每日治疗间的体积变化。
  • 收集膀胱和膀胱三角的Dmax、D0.03 cc、Dmean、V40 Gy、V39 Gy、V38 Gy、V20 Gy剂量参数,以及医生评分(常见不良事件评价标准4.03版)和患者报告(国际前列腺症状评分和扩展前列腺癌指数综合-26评分)的急性泌尿生殖毒性结局。

主要发现

  • 膀胱平均治疗体积较模拟膀胱体积小约30%,膀胱三角体积与总膀胱体积正相关但保持相对一致。
  • 膀胱三角占膀胱体积<2%;膀胱中位Dice相似系数0.79,膀胱三角中位Dice相似系数仅0.33。
  • 所选膀胱和膀胱三角剂量参数与≥2级泌尿生殖毒性无统计学显著关联;数值上,≥2级泌尿生殖毒性患者膀胱中等剂量(V20 Gy和Dmean)更高、膀胱三角高剂量暴露体积(V40 Gy、V39 Gy和V38 Gy)更大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Emerging data suggest that trigone dosimetry may be more associated with poststereotactic body radiation therapy (SBRT) urinary toxicity than whole bladder dosimetry. We quantify the dosimetric effect of interfractional displacement and deformation of the whole bladder and trigone during prostate SBRT using on-board, pretreatment 0.35T magnetic resonance images (MRI). METHODS AND MATERIALS: Seventy-seven patients treated with MRI-guided prostate SBRT (40 Gy/5 fractions) on the MRI arm of a phase 3 single-center randomized trial were included. Bladder and trigone structures were contoured on images obtained from a 0.35T simulation MRI and 5 on-board pretreatment MRIs. Dice similarity coefficient (DSC) scores and changes in volume between simulation and daily treatments were calculated. Dosimetric parameters including Dmax, D0.03 cc, Dmean, V40 Gy, V39 Gy, V38 Gy, and V20 Gy for the bladder and trigone for the simulation and daily treatments were collected. Both physician-scored (Common Terminology Criteria for Adverse Events, version 4.03 scale) as well as patient-reported (International Prostate Symptom Scores and the Expanded Prostate Cancer Index Composite-26 scores) acute genitourinary (GU) toxicity outcomes were collected and analyzed. RESULTS: The average treatment bladder volume was about 30% smaller than the simulation bladder volume; however, the trigone volume remained fairly consistent despite being positively correlated with total bladder volume. Overall, the trigone accounted for <2% of the bladder volume. Median DSC for the bladder was 0.79, whereas the median DSC of the trigone was only 0.33. No statistically significant associations between our selected bladder and trigonal dosimetric parameters and grade ≥2 GU toxicity were identified, although numerically, patients with GU toxicity (grade ≥2) had higher intermediate doses to the bladder (V20 Gy and Dmean) and larger volumes exposed to higher doses in the trigone (V40 Gy, V39 Gy, and V38 Gy). CONCLUSIONS: The trigone exhibits little volume change, but considerable interfractional displacement/deformation. As a result, the relative volume of the trigone receiving high doses during prostate SBRT varies substantially between fractions, which could influence GU toxicity and may not be predicted by radiation planning dosimetry.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Neilsen BK, Ma TM, Akingbemi WO, et al. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37871887. doi:10.1016/j.ijrobp.2023.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。